Grail Stock Drops 47.9% on Missed Primary Endpoint and Investor Probe
Grail shares plunged 47.9% premarket after NHS-Galleri trial missed its primary endpoint despite over 20% reduction in Stage IV diagnoses during second and third annual screenings. Johnson Fistel launched a probe into securities law compliance while Grail pursues FDA approval and expands its U.S. sales force.
1. NHS-Galleri Trial Results
Grail’s three-year NHS-Galleri trial included 142,000 participants aged 50 to 77, comparing annual Galleri plus standard care screening against standard care alone. The trial failed to meet its primary endpoint but achieved over a 20% reduction in Stage IV cancer diagnoses in both the second and third annual screening rounds across 12 deadly cancers.
2. Stock Price Reaction
Grail shares plunged 47.9% in Friday’s premarket session, sharply underperforming broader market gains. The stock is trading more than 40% below its 100-day moving average, with a neutral RSI and bearish MACD signaling potential further volatility.
3. Legal and Regulatory Scrutiny
Investor law firm Johnson Fistel opened an investigation into whether Grail executives fully disclosed critical trial results under federal securities laws. The company’s premarket approval application for Galleri remains under review by the U.S. Food and Drug Administration.
4. Financial Performance and Expansion Plans
Grail reported a quarterly loss of $2.44 per share, beating the $2.73 loss estimate, and posted $43.6 million in revenue, roughly in line with forecasts. The firm completed analysis of its 35,000-participant PATHFINDER 2 study and plans to bolster its U.S. sales force based on the latest trial outcomes.